Clinical trial
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
NCT01900249 is registered in ClinicalTrials.gov with Rigel Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
- Lead sponsor
- Rigel Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2013
- Completion date
- July 31, 2014
- Enrollment
- 204 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.